文献速递骨软组织肉瘤与黑色素瘤

晚期黑色素瘤抗PD-1治疗进展后单用伊匹木单抗或联合纳武利尤单抗

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
PubMed 文献 · Eur J Cancer · 2017-02-17

多中心回顾性研究纳入抗PD-1治疗失败后的晚期黑色素瘤患者,47例接受伊匹木单抗单药,37例接受伊匹木单抗联合纳武利尤单抗。两组客观缓解率分别为16%和21%,疾病控制率分别为42%和33%,1年总生存率分别为54%和55%。作者认为伊匹木单抗可作为抗PD-1治疗失败后的可行选择,而联合方案在此背景下疗效显著低于初治患者。

要点

  • 抗PD-1治疗失败后,伊匹木单抗单药客观缓解率16%,疾病控制率42%,1年总生存率54%。
  • 伊匹木单抗联合纳武利尤单抗客观缓解率21%,疾病控制率33%,1年总生存率55%。
  • 作者认为伊匹木单抗应被视为抗PD-1治疗失败后的可行治疗选择,联合方案疗效显著低于初治患者。

核心结论

  • 作者认为伊匹木单抗应被视为既往抗PD-1治疗失败患者的可行治疗选择,包括最佳疗效为疾病进展者。
  • 伊匹木单抗联合纳武利尤单抗在此背景下疗效显著低于初治患者。

研究设计与样本

  • 多中心回顾性研究,纳入抗PD-1治疗失败后接受纳武利尤单抗(1或3 mg/kg)联合伊匹木单抗(1或3 mg/kg)或伊匹木单抗(3 mg/kg)单药治疗的晚期黑色素瘤患者。
  • 共47例接受伊匹木单抗单药(ipi组),37例接受伊匹木单抗联合纳武利尤单抗(联合组)。
  • 分析患者、肿瘤及治疗前后特征。

主要发现

  • ipi组与联合组客观缓解率分别为16%与21%。
  • ipi组疾病控制率为42%,联合组为33%。
  • ipi组与联合组1年总生存率分别为54%与55%。

临床怎么用

  • 作者认为伊匹木单抗应被视为既往抗PD-1治疗失败晚期黑色素瘤患者的可行治疗选择,包括最佳疗效为疾病进展者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The anti-programmed cell death-1 (PD-1) inhibitors pembrolizumab and nivolumab alone or in combination with ipilimumab have shown improved objective response rates and progression-free survival compared to ipilimumab only in advanced melanoma patients. Anti-PD-1 therapy demonstrated nearly equal clinical efficacy in patients who had progressed after ipilimumab or were treatment-naïve. However, only limited evidence exists regarding the efficacy of ipilimumab alone or in combination with nivolumab after treatment failure to anti-PD-therapy. PATIENTS AND METHODS: A multicenter retrospective study in advanced melanoma patients who were treated with nivolumab (1 or 3 mg/kg) and ipilimumab (1 mg or 3 mg/kg) or ipilimumab (3 mg/kg) alone after treatment failure to anti-PD-1 therapy was performed. Patient, tumour, pre- and post-treatment characteristics were analysed. RESULTS: In total, 47 patients were treated with ipilimumab (ipi-group) and 37 patients with ipilimumab and nivolumab (combination-group) after treatment failure to anti-PD-1 therapy. Overall response rates for the ipi- and the combination-group were 16% and 21%, respectively. Disease control rate was 42% for the ipi-group and 33% for the combination-group. One-year overall survival rates for the ipi- and the combination-group were 54% and 55%, respectively. CONCLUSIONS: Ipilimumab should be considered as a viable treatment option for patients with failure to prior anti-PD-1 therapy, including those with progressive disease as best response to prior anti-PD-1. In contrast, the combination of ipilimumab and nivolumab appears significantly less effective in this setting compared to treatment-naïve patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Zimmer L, Apuri S, Eroglu Z, et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 2017. PMID: 28214657. doi:10.1016/j.ejca.2017.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。